Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MDCK cell-based quadrivalent influenza virus split vaccine
- Development stage
- Unknown
- Lead developer
- Olymvax
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MDCK cell-based quadrivalent influenza virus split vaccine is an inactivated influenza vaccine produced using Madin-Darby Canine Kidney (MDCK) cell culture technology. Unlike traditional egg-based vaccines, this manufacturing process utilizes mammalian cell lines to propagate the virus, which helps maintain the antigenic integrity of the circulating strains by avoiding egg-adaptive mutations. The vaccine is 'split,' meaning the virus particles are chemically disrupted to reduce reactogenicity while maintaining immunogenicity. As a quadrivalent formulation, it contains antigens (hemagglutinin) from four influenza strains: two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). It is being evaluated for safety and immunogenicity in individuals aged 3 years and older.
- Other names
- MDCK cell-based quadrivalent split influenza vaccine
02
Targets
HA (Hemagglutinin (influenza B/Yamagata lineage))HA (Hemagglutinin of influenza B/Victoria lineage)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)NeuraminidaseHA (Hemagglutinin of influenza A/H3N2 strain)
Beyond the preview
Go deeper on MDCK cell-based quadrivalent influenza virus split vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MDCK cell-based quadrivalent influenza virus split vaccine.